Menu Search
Equities

Guard Therapeutics International AB (publ)

5LH0:MUN

Guard Therapeutics International AB (publ)

Actions
  • Price (EUR)1.74
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-35.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-87.20m
  • Incorporated2008
  • Employees6.00
  • Location
    Guard Therapeutics International AB (publ)Guard Therapeutics, Nybrogatan 34, 2 trSTOCKHOLM 114 39SwedenSWE
  • Phone+46 86706551
  • Websitehttps://guardtherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.